Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
05/2005
05/18/2005CN1202130C Solid, stable and concentrated type ortho-silicis acid complex based on bio-absorption, and its prepn. method
05/18/2005CN1202129C GDNF mutant and its medical application
05/18/2005CN1202123C Crystalline forms of IS-[la(pha(2S, 3R),9alpha]-6,10-dioxo-N-(2-ethoxy-5-oxo-tetrahydro-3-furanyl)-9-[[(1-isoquinolyl) carbonyl]-amino] actahydro-6H-piridazino [1,2-A] [1,2] diazepin-1-carboxamide
05/18/2005CN1202118C Adenosine derivatives
05/18/2005CN1202108C Spiro compounds, preparing method and intermediate
05/18/2005CN1202104C 2-phenylpyran-4-one derivatives
05/18/2005CN1202103C Preparation method of red sageroot total phenolic acid
05/18/2005CN1202096C 2-aminothiazoline derivatives and their use as no-synthase inhibitors
05/18/2005CN1202093C Substituted heterocyclic compound
05/18/2005CN1202087C Derivatives of acyl-piperazinil-pyrimidins, preparation thereof and application as medicaments
05/18/2005CN1201822C Compositions comprising sympathomimetic amine salts unsuitable for illegal use
05/18/2005CN1201781C Medicine compositions for treating head-ache, and its prepn. method
05/18/2005CN1201775C Medicine for treating insomnia and preparation thereof
05/18/2005CN1201755C Sobering-up agent
05/18/2005CN1201754C Chinese medicine prepn for giving up drinking wine and its prepn process
05/18/2005CN1201752C Patent Chinese medicine for preventing lung cancer and relieving tabacism and preparation method thereof
05/18/2005CN1201732C Oral pharmaceutical forms of administration with a delayed action
05/17/2005US6894185 Substituted chiral allosteric hemoglobin modifiers
05/17/2005US6894168 Carbamoyl tetrahydropyridine derivatives
05/17/2005US6894155 Immumodulatory protein for use in the treatment of nervous system, skin and immunological disorders
05/17/2005US6894076 Analgesics
05/17/2005US6894067 5-heteroatom-substituted pyrazoles
05/17/2005US6894065 For therapy of thrombosis, platelet aggregation, coagulation, cancer, inflammatory diseases or respiratory diseases
05/17/2005US6894061 Substituted dihydrophenanthridinesulfonamides
05/17/2005US6894058 Administering statin drug
05/17/2005US6894054 Central nervous system disorders; muscular disorders
05/17/2005US6894053 Potentiators of serotonin reuptake inhibitors; cyclohexane carboxylic acid-((1r)-1-cyclohexylmethyl-2-(4-(2-methoxy phenyl)-piperazin-1-yl)ethyl)amide derivatives
05/17/2005US6894052 Serotonergic receptor antagonist
05/17/2005US6894050 3,4,5,6-tetrahydro-2h-(1,2')bipyrazinyl derivatives
05/17/2005US6894047 Triazine compounds useful as sorbitol dehydrogenase inhibitors
05/17/2005US6894045 Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
05/17/2005US6894044 Treatment of depression, anxiety, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, respiratory diseases, inflammatory diseases, neuropathy, immune disorders, etc.
05/17/2005US6894043 Benzothiadiazine derivatives, preparation method and pharmaceutical compositions containing same
05/17/2005US6894042 Azabicyclic compounds for the treatment of disease
05/17/2005US6894041 Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes
05/17/2005US6894033 Combination therapies using vitamin B12 and therapeutic agents for treatment of viral, proliferative and inflammatory diseases
05/17/2005US6894032 Or salt thereof
05/17/2005US6893858 Human kcnq5 potassium channel, methods and compositions thereof
05/17/2005US6893841 Nucleotide sequences coding polypeptide for use in tool in treatment of defects in protein transport
05/17/2005US6893641 Ganoderma lucidum spores for treatment of autoimmune diseases
05/17/2005US6893627 Method for treating type 2 diabetes with an extract of Artemisia
05/17/2005CA2402712C Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease
05/17/2005CA2335492C Pyrrolo[2,3-d]pyrimidine compounds
05/17/2005CA2304987C Inhibition of an fgf-binding protein using ribozymes
05/17/2005CA2267945C Anticonvulsant derivatives useful in treating neuropathic pain
05/17/2005CA2252907C Novel 2,3 disubstituted-4(3h)-quinazolinones
05/17/2005CA2115151C Tau/neurofilament protein kinases pk40 and pk36
05/12/2005WO2005042727A2 Methods of organ regeneration
05/12/2005WO2005041993A1 Use of extracts from the pelargonium species
05/12/2005WO2005041967A1 Transdermal preparations and method for relieving side effects in pergolide therapy
05/12/2005WO2005041956A1 Pharmaceutical compositions based on idazoxan salt or one of the polymorphs thereof
05/12/2005WO2005018531A3 Pharmaceutical compositions, azo-heterocyclic compounds and method for the production and use thereof
05/12/2005WO2005016514A3 Combinatorial synthesis on support
05/12/2005WO2005009343A3 A1 adenosine receptor antogonists
05/12/2005WO2005002572A3 Use of [3.2.0] heterocyclic compounds and analogs thereof for the treatment of cancer, inflammation and infectious diseases
05/12/2005WO2004089312A3 New piperidinylamino-thieno[2,3-d] pyrimidine compounds
05/12/2005WO2004048321A8 Phenylsulfoxide and phenylsulfone derivatives
05/12/2005WO2004009590A8 4-amino-substituted pyrimidine derivatives
05/12/2005WO2003070903A3 RNA INTERFERENCE MEDIATED INHIBITION OF GRB2-ASSOCIATED BINDING PROTEIN 2 (GAB2) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
05/12/2005WO2001079525A3 Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
05/12/2005US20050101788 Method for manufacture of sertindole
05/12/2005US20050101779 Antagonistic activity to alpha 4 integrin; antiinflammatory agents treating asthma, rheumatoid arthritis, inflammatory bowel diseases, lupus, diabetes; 1-[[(cyclohexyloxy)carbonyl]oxy]ethyl(2S)-2-[(2,6-dichlorobenzoyl)amino]-3-[4-[1-methyl-2,4-dioxo-1,4-tetrahydro-3-(2H)quinazolinyl]phenyl]Propionate
05/12/2005US20050101769 CD40-interacting and TRAF-interacting proteins
05/12/2005US20050101665 Treatment of neurotic disorders
05/12/2005US20050101664 Anionically coupling an acyl imidazoyl carbamate with a primary amide or carbamate; N-alkylation; inosine-5*-monophosphate dehydrogenase inhibitors
05/12/2005US20050101662 Such as coumarin, dicoumarol, 7-hydroxycoumarin (umbelliferone), 6,7- dihydroxycoumarin (exculetin), 3,6,7 trihydroxycoumarin, warfarin, or warfarin sodium; cancer, Alzheimer's disease, gout, atherosclerosis, restenosis
05/12/2005US20050101653 Combination therapy for the treatment of migraine
05/12/2005US20050101649 nicotinic alpha 7 receptor and 5-HT3 or 5-HT6 receptor; control of cholinergic and dopaminergic neurotransmission; disorders of the central nervous system and serotonergic hyperactivity; psychiatric and neurodegenerativce disorders; antiemetics during chemotherapy
05/12/2005US20050101641 Aromatic sulfone hydroxamic acids and their use as protease inhibitors
05/12/2005US20050101633 spinal cord injury, spinal cord ischemia-reprefusion injury; P-sulfonamido- or carboxamido phenyl esters of pivalic acid; N-[o-(p-pivaloyloxybenzenesulfonylamino)benzoyl]glycine monosodium salt tetrahydrate; elastase inhibitor; no side effects; inhibited accumulation and infiltration of neutrophil
05/12/2005US20050101614 Heterocyclic GABAA subtype selective receptor modulators
05/12/2005US20050101612 Use of indole-3-acetic acids in the treatment of asthma, copd and other diseases
05/12/2005US20050101610 Antiischemic agents; brain disorders; cardiovascular disorders; for the alleviation or treatment of symptoms due to neurodegenerative diseases and symptoms derived from diabetes, arteriosclerosis and inflammatory diseases ; for example, N-tert-butoxycarbonyl-4-[4-(4-fluorophenoxy)phenyl]-4-piperidinol
05/12/2005US20050101591 Fused bicyclic pyridine derivative as tachykinin receptor antagonist
05/12/2005US20050101585 Cannabis-1 (CB1) receptor antagonists; for treatment/inhibiton of drug induced obesity in juveniles/adolescents
05/12/2005US20050101584 Selective estrogen receptor-beta ligands
05/12/2005US20050101563 Using cyclooxygenase inhbitor and fatty acid; analgesics; antiinflammatory agents; antiarthritic agents; vision defects; urogenital disorders; gastrointestinal disorders
05/12/2005US20050101556 Genetic engineering; Alzheimer's disease; anticancer agents
05/12/2005US20050101552 Neurodegenerative disease; demyelination diseases; brain disorders; screening stem cells in brain; animal models; Alzheimer's, Parkinson's, Huntington's disease
05/12/2005US20050101543 Treatments for neurogenetic disorders, impulse control disorders, and wound healing
05/12/2005US20050101539 Tripeptide derivatives for the treatment of postlesional diseases of the nervous system
05/12/2005US20050101538 particularly Alzheimer's disease and mild cognitive impairment; neurotrophines
05/12/2005US20050101529 Protein modification and maintenance molecules
05/12/2005US20050101527 Method for treating the central nervous system by administration of igf structural analogs
05/12/2005US20050101524 Using arsenic oxide, or complex thereof; angiogenesis inhibitors; anticarcinogenic agents; neurodegenerative agents; antiischemic agents
05/12/2005US20050101014 Oligodendrocytes derived from human embryonic stem cells for remyelination and treatment of spinal cord injury
05/12/2005US20050100918 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100917 Mammalian receptor proteins; related reagents and methods
05/12/2005US20050100907 Method and medicament for inhibiting the expression of a given gene
05/12/2005US20050100902 5-cyano-1h-indole derivatives as antagonist of the inerleukine-8 receptors
05/12/2005US20050100901 Vaccine for treating nicotine addiction
05/12/2005US20050100894 Novel mitogen activated kinase
05/12/2005US20050100536 Platelet rich plasma, no exogenous activator; sodium bicarbonate buffer, citrate dextrose anticoagulant
05/12/2005US20050100534 firoin and firoin-A from extremophilic microorganisms ; active protection and stabilization of skin cells and their organic constituents (proteins, enzymes, membranes, nucleic acids or antioxidants); against damaging environmental influences, UV radiation.
05/12/2005CA2553156A1 Composition and dosage form for sustained effect of levodopa
05/12/2005CA2544350A1 N-substituted benzene sulfonamides
05/12/2005CA2544332A1 Use of a hydroximic acid halide derivative in the treatment of neurodegenerative diseases
05/12/2005CA2544310A1 New fused polycyclic compounds having a heterocyclic ring(s) and pharmaceutical use thereof
05/12/2005CA2544297A1 Use of 2-thia-dibenzo[e, h]azulenes for the manufacture of pharmaceutical formulations for the treatment and prevention of central nervous system diseases and disorders
05/12/2005CA2544050A1 Use of plant parts of prickly pear (opuntia) and/or extracts therefrom for the treatment of depressions
1 ... 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 ... 1833